~1/3 non-IPF ILD progresses over time. KL-6, a new biomarker, retro study of 10 European centers, 303 pts - 37% progressed (⩾10% FVC decline) after 1yr. 5 predictors of progression: age, gender, BMI, FVC, KL-6. (superior to KL-6 alone) w/ 55% sensitivity, 73% specificity 67% https://t.co/i0Uc8DPHaM